Bio-Techne teams up with Leica to bring RNAscope to Europe

By LabPulse.com staff writers

May 27, 2020 -- Global life sciences firm Bio-Techne and pathology workflow software developer Leica Biosystems have launched Bio-Techne's RNAscope in situ hybridization detection kit on Leica's Bond-III workflow automation platform in Europe.

The kit, which has received the CE-IVD Mark in Europe, will enable pathologists to evaluate biomarkers involved in cancer, infection, and other prevalent diseases, according to the companies. Specifically, the RNAscope kit and probes identify RNA expression patterns and localization at the single cell level with spatial and morphologic context, the companies said.
Telepathology: Part 2 -- Putting plans into action
The COVID-19 crisis is giving a boost to telepathology. Transitioning from reading pathology slides on a microscope to reading them electronically on...
Clinical diagnostics and the artificial intelligence boom
Artificial intelligence (AI) is becoming increasingly common in our everyday lives, but the role of AI in clinical diagnostics is the subject of intense...
Leica, Sectra plan joint FDA filing in digital pathology
Pathology workflow solutions company Leica Biosystems and medical imaging specialist Sectra plan to jointly file for 510(k) clearance from the U.S. Food...
AACC preview: A rough guide to diagnostics on show
Bruce Carlson, longtime diagnostic market analyst and publisher of Kalorama Information, takes you on a trip through this year's product offerings at...
Bio-Techne's prostate cancer test lands FDA breakthrough status
Bio-Techne's ExoDx Prostate IntelliScore liquid biopsy test for spotting aggressive prostate cancers has received the U.S. Food and Drug Administration's...

Copyright © 2020 LabPulse.com

Last Updated ls 5/27/2020 8:29:45 AM